Stoke Therapeutics, Inc. (STOK) Q3 2022 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Stoke Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.029 -- 00:00:03.812 Good morning. My name is Audra and I will be your conference operator today. 00:00:03.812 -- 00:00:08.395 At this time, I would like to welcome everyone to the Stoke Therapeutics interim analysis 00:00:08.395 -- 00:00:12.878 of STK001 for the treatment of Dravet syndrome. 00:00:12.878 -- 00:00:16.320 All lines have been placed on mute to prevent any background noise. 00:00:16.320 -- 00:00:19.883 After the speaker's remarks, there will be a question and answer session. 00:00:19.883 -- 00:00:23.505 If you would like to ask a question during this time, simply press the star key followed 00:00:23.505 -- 00:00:26.047 by the number one on your telephone keypad. 00:00:26.047 -- 00:00:29.818 If you would like to withdraw your question, press star one again. 00:00:29.818 -- 00:00:33.880 At this time, I'd like to turn the conference over to Eric Rojas, Head of Investor Relations. 00:00:33.880 -- 00:00:35.821 Please go ahead. 00:00:35.821 -- 00:00:40.044 Thanks, Audra, and good morning. This is Eric Rojas, Head of Investor Relations at Stokes 00:00:40.044 -- 00:00:44.606 Therapeutics. On today's call, we will discuss results from the interim analysis of the 00:00:44.606 -- 00:00:49.949 Phase 1-2A clinical studies of our investigational medicine STK001 00:00:49.949 -- 00:00:53.231 for the treatment of Gervais syndrome. Our speakers today are Dr. 00:00:53.231 -- 00:00:58.638 Edward Kay, Stokes CEO, and Dr. Barry Tico, Stokes Chief Medical Officer. 00:00:58.638 -- 00:01:03.182 As you listen to this call, we recommend that you access the webcast slides in the Investors 00:01:03.182 -- 00:01:08.746 section on our website. This call is being recorded, and a replay will also be available 00:01:08.746 -- 00:01:11.669 on the Stoke website later today....